]>
IRCT20140802018655N6 IRCT 2021-01-06 Shiraz University of Medical Sciences The effect of bromocriptine on endometrioma size The evaluation of therapeutic effect of dopamine agonist (bromocriptine) on endometrioma size 2018-12-22 anticipated 60 Complete https://irct.ir/trial/16857 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sample size was 60 participants (30 people in each group). The block randomization method was developed by an epidemiologist collaborator using version 13 of Stata software. To conceal the random allocation process, 60 treatment cards were written in sequential order, then the cards were placed in sealed envelopes. On each envelope, a random code was written with no sequences that only the methodologist was aware of the code. When the physician announced a patient's eligibility, the methodologist provided the envelope, Blinding description: The person who evaluated the final outcomes was unaware of the random allocation process and the type of treatment performed. Data were analyzed by a statistical expert who was separated from the study process and unaware of all the processes performed. 2 Endometrioma. Intervention 1: Intervention group: Received medroxyprogesterone 20 mg with Bromocriptine 1/25 mg twice daily for at least 3 months. Intervention 2: Control group: Received medroxyprogesterone 20 mg twice daily with placebo for at least 3 months. Yes - There is a plan to make this available What will be shared: Study data is accessible by observing moral points of view on the confidentiality of patient information. When: Immediately after the publication of the article To whom: Gynecology specialists in coordination with the presenter Conditions: Meta-analysis is allowed on the data of this study. Where to obtain: Dr.Tahereh Poordast, Madar o Kodak Hospital, Emam Reza Boulevard, Siraz, Iran , Email: ta.poordast@yahoo.com How to obtain: After one year of publishing the article and publishing the results, those who need the data of this study could apply via email. Comments:
public Tahereh Poordast
Madar o Kodak Hospitall, EmamReza Boulevard
Shiraz Iran (Islamic Republic of) 71348-14336 +98 71 3230 4596 ta.poordast@yahoo.com Shiraz University of Medical Sciences scientific Tahereh Poordast
Madar o Kodak Hospitall, Emam Reza Boulevard
Shiraz Iran (Islamic Republic of) 71348-14336 +98 71 3233 2365 ta.poordast@yahoo.com Shiraz University of Medical Sciences Iran (Islamic Republic of) A definitive diagnosis of endometrioma 18 years 45 years Female patients with hyperprolactinemia People with coagulation disorders who have contraindications to medroxyprogesterone N80.1 Endometriosis of ovary Treatment - Drugs Treatment - Drugs Intervention group: Received medroxyprogesterone 20 mg with Bromocriptine 1/25 mg twice daily for at least 3 months Control group: Received medroxyprogesterone 20 mg twice daily with placebo for at least 3 months Endometrioma size. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: Ultrasonography. Pain pelvic. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: VAS test. Dysmenorrhea. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: VAS test. Dyspareunia. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: VAS test. Shiraz University of Medical Sciences Approved 2020-07-27 Ethics committee of Shiraz University of Medical Sciences Vice Chancellor of research, Shiraz University of Medical Sciences, 7th floor, central building of Shiraz University of Medical Sciences, Zand street Shiraz Fars Iran (Islamic Republic of)